Beruflich Dokumente
Kultur Dokumente
JUST DIAGNOSED
177-Lutetium-Octreotate Therapy
Precautions to be taken
177-Lutetium is radioactive and is not given if you are pregnant. If there any
concerns about pregnancy, a pregnancy test will be done. Reliable birth
control should be used until treatment has finished and for at least 6 months
afterward. Men are advised not to father a child for the same period.
If you are breast-feeding, you must tell your doctor. Breast-feeding must stop
before you have this treatment.
After the 177-Lutetium has been administered, the door to your room will be
closed and there will be minimal nursing care provided. You have a window, a
bathroom, and can rent a TV or telephone. This entire process will take 8-10
hours.
Visitors are restricted to a maximum of three 30 minute visits every 24 hours
for the same visitor. They must stay 1-2 meters from your bed. No physical
contact is permitted.
Discharge Day
A staff member from Nuclear Medicine will come to your room to measure
the radiation levels by 9:00 am. Your door will be opened and you will be
discharged from the inpatient unit to the Nuclear Medicine department where
a post therapy scan will be done. This scan will take at least 90 minutes.
After Discharge
For the first 6 weeks after your treatment, it is recommended you tell any
doctor, nurse or pharmacist you have been treated with 177-LutetiumOctreotate. It is recommended you carry this information brochure and the
radiation card with you at all times. This information will help answer
questions you may be asked.
We plan to administer three 177-Lutetium therapies. They will be
administered every 8-10 weeks based on your blood work results. We will
inform you of the tentative date for the next therapy the day of admission.
Three to four months after the third therapy, a CT scan or MRI and a renal
scan will be arranged to assess the efficacy of the therapy and your kidney
function. You will be provided with a clinic appointment. It is at this
appointment you will receive the results and the next step in your plan of care
will be discussed.
Note
177-Lutetium-Octreotate does not have a license for use in Canada. It is only
available through the Special Access Program with Health Canada. This means
that the results of the rigorous tests with respect to the efficacy of 177Lutetium, side effects, and which patients with neuroendocrine tumours are
more likely to benefit, have not yet been completed.
By law we must obtain your written consent to accept 177-Lutetium
Octreotate therapy. A member of your health care team will discuss the risks,
benefits and alternative treatments with you. If you have any questions about
the treatment, do not hesitate to ask to speak with your physician.
Recommended Lodging
If you need to stay in London the night prior to your admission we
recommend the Country Inn & Suites. They are located almost directly across
from the B Entrance into the London Health Sciences Centre. You can walk
from their parking lot to the hospital. There is a complimentary breakfast
included. They also have special rates for individuals who require the services
of London Health Sciences. As of September 2012, the rate per night for 2
people is $89.00.
www.countryinns.com/london
744 Baseline Road East
1.800.456.4000